1242137-16-1

Basic information

• Product Name: N-desMethyl EnzalutaMide
• Synonyms: N-desMethyl EnzalutaMide;4-[3-[4-Cyano-3-(trifluoroMethyl)phenyl]-5,5-diMethyl-4-oxo-2-thioxo-1-iMidazolidinyl]-2-fluorobenzaMide;Enzalutamide impurity B
• CAS NO: 1242137-16-1
• Molecular Formula: C₂₀H₁₄F₄N₄O₂S
• Molecular Weight: 450.4093728
• Product Categories: Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 1242137-16-1.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Storage Temp.: Amber Vial, Refrigerator
• Solubility: Chloroform (Slightly), DMSO (Slightly), Methanol (Very Slightly, Heated)
• Stability: Light Sensitive
• CAS DataBase Reference: N-desMethyl EnzalutaMide(CAS DataBase Reference)
• NIST Chemistry Reference: N-desMethyl EnzalutaMide(1242137-16-1)
• EPA Substance Registry System: N-desMethyl EnzalutaMide(1242137-16-1)

Safety Data

• Hazardous Substances Data: 1242137-16-1(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 1242137-16-1 differently. You can refer to the following data:
1. N-desMethyl EnzalutaMide is used in the treatment of disorders involving androgen, estrogen and progesterone receptors.
2. 4-[3-[4-Cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-thioxo-1-imidazolidinyl]-2-fluorobenzamide is used in the treatment of disorders involving androgen, estrogen and progesterone receptors.

Upstream product

• 1802242-43-8 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluorobenzoic acid methyl ester 
• 179232-29-2 methyl 4-bromo-2-fluorobenzoate 
• 112704-79-7 2-fluoro-4-bromobenzoic acid 
• 1242137-21-8 methyl 2-(4-carbamoyl-3-fluorophenylamino)-2-methylpropanoate 
• 143782-23-4 4-isothiocyanato 2-(trifluoromethyl)benzonitrile 

Downstream Products

• 1242137-17-2 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-2,4-dioxoimidazolidin-1-yl)-2-fluorobenzamide 

Relevant articles and documents

ENZALUTAMIDE DERIVATIVES FOR THE TREATMENT OF PROSTATE AND BREAST CANCER

The invention provides a compound of formula (I) or (I') or a pharmaceutically acceptable salt thereof. Also provided are pharmaceutical compositions comprising the compounds, processes for preparing the compounds and medical uses of the compounds.

SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOIN COMPOUNDS

Compositions, such as pharmaceutical compositions, comprising specific diarylhydantoin and diarylthiohydantoin compounds, or salts or solvates thereof, are provided. Isolated and purified forms of the compounds are also described, as are unit dosage forms, compositions of substantially pure compound and kits comprising the compounds. The compounds and pharmaceutical compositions thereof may find use in the prevention and/or treatment of a variety of conditions, including prostate cancer, Parkinson's disease, Alzheimer's disease, and others.